[PDF][PDF] Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials …
CM Canil, MJ Moore, E Winquist, T Baetz… - Journal of Clinical …, 2005 - researchgate.net
Journal of Clinical Oncology, 2005•researchgate.net
Purpose Overexpression of the epidermal growth factor receptor has been demonstrated in
advanced prostate cancer and is associated with a poor outcome. A multi-institutional,
randomized, phase II study was undertaken by the National Cancer Institute of Canada-
Clinical Trials Group to evaluate the efficacy and toxicity of two doses of oral gefitinib in
patients with minimally symptomatic, hormone-refractory prostate cancer (HRPC).
advanced prostate cancer and is associated with a poor outcome. A multi-institutional,
randomized, phase II study was undertaken by the National Cancer Institute of Canada-
Clinical Trials Group to evaluate the efficacy and toxicity of two doses of oral gefitinib in
patients with minimally symptomatic, hormone-refractory prostate cancer (HRPC).
Purpose
Overexpression of the epidermal growth factor receptor has been demonstrated in advanced prostate cancer and is associated with a poor outcome. A multi-institutional, randomized, phase II study was undertaken by the National Cancer Institute of Canada-Clinical Trials Group to evaluate the efficacy and toxicity of two doses of oral gefitinib in patients with minimally symptomatic, hormone-refractory prostate cancer (HRPC).
researchgate.net